Clinical Trials Browser

Completed × Has results × enasidenib × Clear all

NCT02577406 2025-05-18

IDHENTIFY

Phase 3 Completed

319 enrolled 29 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid

NCT04281498 2025-02-04

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Phase 2 Completed

6 enrolled 11 charts

Primary Myelofibrosis

NCT01915498 2024-10-22

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Phase 1/2 Completed

345 enrolled 120 charts 1 FDA

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Phase 1/2 Completed

21 enrolled 33 charts

CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma